<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010538</url>
  </required_header>
  <id_info>
    <org_study_id>Sarecycline TASER1</org_study_id>
    <nct_id>NCT05010538</nct_id>
  </id_info>
  <brief_title>Sarecycline Truncal Acne Safety and Efficacy Response</brief_title>
  <acronym>TASER</acronym>
  <official_title>A Single Center, Phase 4, Open-label Prospective Case Series Study of the Safety and Efficacy of Sarecycline for 12 Weeks in Subjects Ages 9 and Over With Truncal Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angela Moore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Almirall, SAS</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arlington Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of oral sarecycline 1.5&#xD;
      mg/kg/day in truncal acne. Patients with moderate to severe acne vulgaris will be observed&#xD;
      over a period of 12 weeks. Lesion counts, investigator's global assessments, photography, and&#xD;
      safety measures will be assessed for the trunk and face.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Actual">June 24, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Acne Severity Based on Investigator's Global Assessment Success</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Investigator's Global Assessment (IGA) success for truncal acne vulgaris at week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Absolute Lesion Count</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Absolute change from baseline lesion counts for inflammatory acne for truncal acne vulgaris at week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Adverse Events of Special Interest</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Safety based on adverse events (AEs), adverse events of special interest (AESI), vital signs, and physical examinations</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Sarecycline</arm_group_label>
    <description>Eligible patients will be prescribed with commercially available sarecycline at a dosage of 1.5 mg/kg/day and followed for 12 weeks post initiation of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarecycline</intervention_name>
    <description>60 mg sarecycline tablets will be given for subjects with a body weight of 33 to 54 kg, 100 mg sarecycline tablets will be given for subjects with a body weight of 55 to 84 kg, and 150 mg tablets will be given for subjects with a body weight between 85 and 136 kg.</description>
    <arm_group_label>Sarecycline</arm_group_label>
    <other_name>SeysaraÂ®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with moderate to severe truncal acne at a single center in Texas, USA.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female age 9 or above.&#xD;
&#xD;
          -  Clinical diagnosis of moderate to severe truncal acne based on IGA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected allergies or sensitivities to any components of the study drug.&#xD;
&#xD;
          -  Any disorders that would preclude the use of tetracycline-class antibiotics or&#xD;
             sarecycline.&#xD;
&#xD;
          -  Any uncontrolled or serious disease, or any medical or surgical condition, that may&#xD;
             either interfere with the interpretation of the trial results and/or put the subject&#xD;
             at significant risk (according to the Investigator's judgment) if the subject takes&#xD;
             part in the trial.&#xD;
&#xD;
        Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Angela Moore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arlington Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arlington Research Center</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Arlington Research Center</investigator_affiliation>
    <investigator_full_name>Angela Moore</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Acne Vulgaris</keyword>
  <keyword>Sarecycline</keyword>
  <keyword>Tetracycline</keyword>
  <keyword>Truncal Acne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarecycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

